Rafael Holdings, Inc. (RFL) Stock Analysis & Investment Frameworks

Rafael Holdings, Inc. (RFL) stock analysis on Invetso. Review Rafael Holdings, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Rafael Holdings, Inc. Company Overview

Rafael Holdings, Inc. Key Financial Metrics

About Rafael Holdings, Inc.

Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.

Rafael Holdings, Inc. Investment Frameworks

Invetso analyzes Rafael Holdings, Inc. (RFL) across the following frameworks:

Explore More RFL Research